Molecular alterations in colorectal adenomas and intramucosal adenocarcinomas defined by high-density single-nucleotide polymorphism arrays

Makoto Eizuka¹ · Tamotsu Sugai¹ · Wataru Habano² · Noriyuki Uesugi¹ · Yayoi Takahashi¹ · Keisuke Kawasaki³ · Eiichiro Yamamoto⁴ · Hiromu Suzuki⁴ · Takayuki Matsumoto³

Received: 28 November 2016 / Accepted: 30 January 2017 / Published online: 14 February 2017
© The Author(s) 2017. This article is published with open access at Springerlink.com

Abstract

Background We examined colorectal adenomas and intramucosal adenocarcinomas (IMAs) to develop a genome-wide overview of copy number alterations (CNAs) during colorectal tumorigenesis.

Methods We analysed CNAs using a high-resolution SNP array of isolated tumour glands obtained from 55 colorectal adenomas (35 low-grade adenomas and 20 high-grade adenomas) and 30 IMAs. Next, we examined whether frequent CNAs differed between low-grade and high-grade adenomas or high-grade adenomas and IMAs. Finally, we investigated the total lengths of the CNAs in low-grade adenomas, high-grade adenomas, and IMAs.

Results Although no frequent CNAs were found in low-grade adenomas, the most frequent alterations of high-grade adenomas were gains of 7q11, 7q21 and 9p13 and loss of 5q14.3-35. High levels of gains were detected at 13q, 7q, 8p, 20q, 7p, 18p and 17p in IMAs. Although no frequent alteration differed between low-grade and high-grade adenomas, significant differences of gains at 13q, 17p and 18p were found between high-grade adenoma and IMAs. Although the total lengths of all CNAs (gains and losses), copy number gains, and losses of heterozygosity were significantly greater in high-grade adenomas than in low-grade adenomas, no significant differences in the lengths of CNAs were found between high-grade adenomas and IMAs.

Conclusions Genomic alterations play an essential role in early colorectal carcinogenesis. CNAs in colorectal tumours provide new insights for evaluation of colorectal tumorigenesis.

Keywords Colorectal adenoma · Copy number alteration · Intramucosal adenocarcinoma · Gain · Loss of heterozygosity

Abbreviations

BAF  B allele frequency
CNA  Copy number alteration
CNLOH  Copy-neutral loss of heterozygosity
CRC  Colorectal cancer
LOH  Loss of heterozygosity
LRR  Log R ratio
SNP  Single-nucleotide polymorphism

Introduction

Although there have been advances in medical treatment of colorectal cancer (CRC) recently, CRC remains a major cause of cancer death in both men and women worldwide.
Colorectal adenoma is a well-known premalignant lesion in colorectal carcinogenesis. Intramucosal cancer is an intermediate lesion between colorectal adenoma and invasive submucosal cancer, which is associated with a high risk of metastasis [2]. If intramucosal cancer is left untreated, it would eventually invade the submucosal layer [2]. Colorectal adenoma and intramucosal cancer (adenocarcinoma) are important lesions for our understanding of early colorectal carcinogenesis [3].

The sequential acquisition of molecular alterations within the adenoma–carcinoma progression is an important theory in the molecular carcinogenesis of CRC [4–6]. Fearon and Vogelstein first proposed the multistep genetic model of colorectal carcinogenesis that is now a paradigm for CRC progression. Inactivation of the adenomatous polyposis coli tumour-suppressor gene (APC) occurs first, followed by activating mutations of KRAS. Next, inactivation of the TP53 gene occurs at the intramucosal cancer stage. Finally, multiple loss-of-heterozygosity (LOH) events accumulate in the invasive stage of CRC [4–6]. Although recent studies have shown that DNA methylation is closely associated with the initial development of CRC [7, 8], genomic alterations are required to achieve invasive ability in the current molecular pathways [6–8]. Advanced array technology has made possible identification of genome-wide alterations in colorectal carcinogenesis. Genomic alterations can be classified into subtypes: copy number gains and copy number losses (both LOH and copy-neutral LOH) [9–11]. Although copy number alterations (CNAs) have been extensively investigated in CRC [12–17], the role of CNAs is not fully understood in the initial stages of colorectal carcinogenesis, particularly colorectal adenoma and intramucosal adenocarcinoma [16, 17].

In this study, we mapped the overall genetic changes in colorectal adenomas (low grade and high grade) and intramucosal adenocarcinomas using high-resolution single-nucleotide polymorphism (SNP) mapping arrays. Our goal was to search for differences in frequent genetic alterations between colorectal adenoma and intramucosal adenocarcinoma samples that may identify candidate genes highly characteristic of malignant transformation from colorectal adenoma. In addition, we aimed to identify genetic alterations between low-grade and high-grade adenomas.

**Materials and methods**

**Patients**

Eighty-five samples were obtained from patients with newly diagnosed colorectal adenoma (55 cases) and intramucosal adenocarcinoma (30 cases) at Iwate Medical University Hospital between December 2014 and August 2016. The colorectal adenomas consisted of 35 low-grade and 20 high-grade cases. Histological classification was performed according to the modified criteria of the WHO classification for colorectal tumours [18]. Intramucosal adenocarcinoma was classified as well-differentiated adenocarcinoma (21 cases) or moderately differentiated adenocarcinoma (9 cases). Poorly differentiated adenocarcinoma was excluded. Clinopathology data are listed in Table 1. The local ethics committees of Iwate Medical University approved the sample collection and study design. General written consent was obtained from all patients.

All samples were processed by the Diagnostic Pathology Laboratory of Iwate Medical University Hospital. Samples were routinely fixed in 10% neutral-buffered formalin.

| Clinicopathology data for the colorectal adenomas and intramucosal adenocarcinomas (IMAs) | Adenomas | IMAs |
|---|---|---|
| Total | 55 | 30 |
| Male | 36 | 21 |
| Female | 19 | 9 |
| Age (years)* | 67.0 (42–90) | 66.5 (48–88) |
| Locus | | |
| Right (C, A, T) | 20 (36.4%) | 9 (30.0%) |
| Left (D, S, R) | 35 (63.6%) | 21 (70.0%) |
| Size (mm)* | 14.0 (7-53) | 15.0 (9-41) |
| Macroscopic type | | |
| Is | 3 (5.5%) | 6 (20.0%) |
| Isp | 21 (38.2%) | 8 (26.7%) |
| Ip | 24 (43.6%) | 3 (10.0%) |
| IIa | 1 (1.8%) | 1 (3.3%) |
| IIC | 0 | 5 (16.7%) |
| LST | 6 (10.9%) | 7 (23.3%) |
| Adenoma component | | |
| TA | 37 (67.3%) | |
| TVA | 18 (32.7%) | |
| Tumour grade | | |
| Low | 35 (63.6%) | |
| High | 20 (36.4%) | |
| Differentiation | | |
| tub1 | 21 (70.0%) | |
| tub2 | 9 (30.0%) | |

*C cecum, A ascending colon, D descending colon, S sigmoid colon, R rectum, LST laterally spreading tumour, TA tubular adenoma, tub1 well-differentiated adenocarcinoma, tub2 moderately differentiated adenocarcinoma, TVA tubulovillous adenoma

* The median is given, with the range in parentheses
Grades of atypia (dysplasia) of colorectal adenoma and definition of intramucosal adenocarcinoma

On the basis of the degree of cytological atypia and abnormal crowding of the epithelium, colorectal adenoma is classified into two categories: low-grade and high-grade colorectal adenoma [18]. Low-grade adenoma is characterized by a uniform monolayer of columnar cells with basal nuclei showing minimal atypia [1]. High-grade adenoma has greater nuclear atypia, with nuclear pleomorphism, nuclear enlargement and pseudostratification. Intramucosal adenocarcinoma has marked cytological atypia and a complex architecture with cribriform groups, irregular branching and budding of neoplastic cells into the lumen [18]. It is common to observe different grades of atypia (dysplasia) within a given lesion, which suggests the development of atypia (dysplasia) from a lower grade to a higher grade. Distinguishing the grade of atypia (dysplasia) is important, as invasive carcinoma is commonly observed in areas of high-grade atypia (dysplasia). In each case, the lesion should be classified according to the highest grade of dysplasia observed.

Crypt isolation and DNA extraction

Crypts were isolated from tumour and normal mucosa samples to obtain pure glands in accordance with a previously reported method [19]. The isolated glands were routinely processed to confirm the nature of the glands by means of paraffin-embedded histological sections. Contamination with other materials such as interstitial cells was not evident in the samples that were examined, as described in previous reports [19, 20].

DNA from normal and tumour glands was extracted by standard sodium dodecyl sulfate–proteinase K treatment. DNA extracted from the samples was resuspended in a buffer of 10 mM tris(hydroxymethyl)aminomethane–HCl and 1 mM EDTA, pH 8.0.

CNA analysis

Analysis of CNAs was performed according to our previous reports [21, 22]. Extracted DNA was adjusted to a concentration of 50 ng/µL. All 85 paired samples were assayed with use of the Infinium HumanCytoSNP-12 v2.1 BeadChip (Illumina, San Diego, CA, USA), which contains 299,140 SNP loci, according to the Illumina Infinium HD assay protocol. BeadChips were scanned by iScan (Illumina) and analysed by GenomeStudio (version 2011.1; Illumina). The log R ratio (LRR) and B allele frequency (BAF) for each sample were exported from normalized Illumina data with use of GenomeStudio. Data were analysed with use of KaryoStudio 1.4.3 (CNV Plugin version 3.0.7.0; Illumina) with default parameters. Chromosomal CNAs were classified by copy number variation partitioning algorithms: LRR = 0 indicated a normal diploid region, LRR > 0 indicated a copy number gain and LRR < 0 indicated a copy number LOH. BAFs ranged from 0 to 1; homozygous SNPs had BAFs near 0 (A allele) or 1 (B allele), and heterozygous diploid region SNPs had BAFs near 0.5 (AB genotype). Additionally, LRR and BAF data were used to identify regions of hemizygous and copy-neutral LOH.

Calculation of CNA length on a genome-wide scale in CRCs

To quantify CNAs on a genome-wide scale, we calculated the total lengths of CNAs (losses plus gains), total length of copy number gains, total length of copy number LOH events and total length of copy-neutral LOH events identified by the SNP array analysis, as previously described [21, 22]. We used the total CNA length as an index representing the degree of chromosomal alterations and assessed the relationship between CNA length (total CNA, gain, LOH and copy-neutral LOH) and low-grade adenoma, high-grade adenoma or intramucosal adenocarcinoma.

Statistical analysis

Data obtained for CNAs based on each subgroup were analysed by chi-square tests with Yates’s correction with the aid of Stat Mate-III (Atom, Tokyo, Japan). In addition, differences in the total lengths of CNAs between the three groups were analysed by Kruskal–Wallis tests (Prism 6; GraphPad Software, La Jolla, CA, USA). If statistical differences between the three groups were found, statistical analysis of the two groups was further performed by Mann–Whitney U tests (Prism 6) with Bonferroni corrections. Differences with \( P < 0.05 \) were regarded as significant.
Results

Genomic alterations in colorectal adenomas and intramucosal adenocarcinomas

The 85 pairs of colorectal adenoma and intramucosal adenocarcinoma samples were examined with use of SNP arrays to detect CNAs in colorectal adenomas (low-grade and high-grade adenomas) and intramucosal adenocarcinomas (Fig. 1). The frequency of CNAs was detected across the entire genome. In colorectal adenomas, the mean total number of chromosomal aberrations per patient was 59, with the number of gains averaging 32 and ranging from 0 to 163, the number of LOHs averaging 5 and ranging from 0 to 83, and the number of copy-neutral LOHs averaging 22 and ranging from 0 to 153. Next, we examined genomic alterations on the basis of the grade of atypia (dysplasia) in colorectal adenomas. In low-grade colorectal adenomas, the mean number of total chromosomal aberrations was 28 per patient, with the number of gains averaging 13 and ranging from 0 to 45, the number of LOHs averaging 3 and ranging from 0 to 21, and the number of copy-neutral LOHs averaging 12 and ranging from 0 to 68. In high-grade colorectal adenomas, the mean number of total chromosomal aberrations per patient was 113, with the number of gains averaging 64 and ranging from 0 to 163, the number of LOHs averaging 11 and ranging from 0 to 83, and the number of copy-neutral LOHs averaging 38 and ranging from 0 to 153. In intramucosal adenocarcinomas, on the other hand, the mean number of total chromosomal aberrations per patient was 168, with the number of gains averaging 126 and ranging from 0 to 357, the number of LOHs averaging 11 and ranging from 0 to 67, and the number of copy-neutral LOHs averaging 31 and ranging from 0 to 132. We searched for minimal common CNA regions in colorectal adenomas, the mean number of total chromosomal aberrations was 28 per patient, with the number of gains averaging 13 and ranging from 0 to 45, the number of LOHs averaging 3 and ranging from 0 to 21, and the number of copy-neutral LOHs averaging 12 and ranging from 0 to 68. In high-grade colorectal adenomas, the mean number of total chromosomal aberrations per patient was 113, with the number of gains averaging 64 and ranging from 0 to 163, the number of LOHs averaging 11 and ranging from 0 to 83, and the number of copy-neutral LOHs averaging 38 and ranging from 0 to 153. In intramucosal adenocarcinomas, on the other hand, the mean number of total chromosomal aberrations per patient was 168, with the number of gains averaging 126 and ranging from 0 to 357, the number of LOHs averaging 11 and ranging from 0 to 67, and the number of copy-neutral LOHs averaging 31 and ranging from 0 to 132. We searched for minimal common CNA regions in colorectal adenomas, the mean number of total chromosomal aberrations was 28 per patient, with the number of gains averaging 13 and ranging from 0 to 45, the number of LOHs averaging 3 and ranging from 0 to 21, and the number of copy-neutral LOHs averaging 12 and ranging from 0 to 68. In high-grade colorectal adenomas, the mean number of total chromosomal aberrations per patient was 113, with the number of gains averaging 64 and ranging from 0 to 163, the number of LOHs averaging 11 and ranging from 0 to 83, and the number of copy-neutral LOHs averaging 38 and ranging from 0 to 153. In intramucosal adenocarcinomas, on the other hand, the mean number of total chromosomal aberrations per patient was 168, with the number of gains averaging 126 and ranging from 0 to 357, the number of LOHs averaging 11 and ranging from 0 to 67, and the number of copy-neutral LOHs averaging 31 and ranging from 0 to 132. We searched for minimal common CNA regions in colorectal adenomas, the mean number of total chromosomal aberrations was 28 per patient, with the number of gains averaging 13 and ranging from 0 to 45, the number of LOHs averaging 3 and ranging from 0 to 21, and the number of copy-neutral LOHs averaging 12 and ranging from 0 to 68. In high-grade colorectal adenomas, the mean number of total chromosomal aberrations per patient was 113, with the number of gains averaging 64 and ranging from 0 to 163, the number of LOHs averaging 11 and ranging from 0 to 83, and the number of copy-neutral LOHs averaging 38 and ranging from 0 to 153. In intramucosal adenocarcinomas, on the other hand, the mean number of total chromosomal aberrations per patient was 168, with the number of gains averaging 126 and ranging from 0 to 357, the number of LOHs averaging 11 and ranging from 0 to 67, and the number of copy-neutral LOHs averaging 31 and ranging from 0 to 132. We searched for minimal common CNA regions in colorectal adenomas, the mean number of total chromosomal aberrations was 28 per patient, with the number of gains averaging 13 and ranging from 0 to 45, the number of LOHs averaging 3 and ranging from 0 to 21, and the number of copy-neutral LOHs averaging 12 and ranging from 0 to 68. In high-grade colorectal adenomas, the mean number of total chromosomal aberrations per patient was 113, with the number of gains averaging 64 and ranging from 0 to 163, the number of LOHs averaging 11 and ranging from 0 to 83, and the number of copy-neutral LOHs averaging 38 and ranging from 0 to 153. In intramucosal adenocarcinomas, on the other hand, the mean number of total chromosomal aberrations per patient was 168, with the number of gains averaging 126 and ranging from 0 to 357, the number of LOHs averaging 11 and ranging from 0 to 67, and the number of copy-neutral LOHs averaging 31 and ranging from 0 to 132. We searched for minimal common CNA regions in colorectal adenomas, the mean number of total chromosomal aberrations was 28 per patient, with the number of gains averaging 13 and ranging from 0 to 45, the number of LOHs averaging 3 and ranging from 0 to 21, and the number of copy-neutral LOHs averaging 12 and ranging from 0 to 68. In high-grade colorectal adenomas, the mean number of total chromosomal aberrations per patient was 113, with the number of gains averaging 64 and ranging from 0 to 163, the number of LOHs averaging 11 and ranging from 0 to 83, and the number of copy-neutral LOHs averaging 38 and ranging from 0 to 153. In intramucosal adenocarcinomas, on the other hand, the mean number of total chromosomal aberrations per patient was 168, with the number of gains averaging 126 and ranging from 0 to 357, the number of LOHs averaging 11 and ranging from 0 to 67, and the number of copy-neutral LOHs averaging 31 and ranging from 0 to 132. We searched for minimal common CNA regions in colorectal adenomas, the mean number of total chromosomal aberrations was 28 per patient, with the number of gains averaging 13 and ranging from 0 to 45, the number of LOHs averaging 3 and ranging from 0 to 21, and the number of copy-neutral LOHs averaging 12 and ranging from 0 to 68. In high-grade colorectal adenomas, the mean number of total chromosomal aberrations per patient was 113, with the number of gains averaging 64 and ranging from 0 to 163, the number of LOHs averaging 11 and ranging from 0 to 83, and the number of copy-neutral LOHs averaging 38 and ranging from 0 to 153. In intramucosal adenocarcinomas, on the other hand, the mean number of total chromosomal aberrations per patient was 168, with the number of gains averaging 126 and ranging from 0 to 357, the number of LOHs averaging 11 and ranging from 0 to 67, and the number of copy-neutral LOHs averaging 31 and ranging from 0 to 132. We searched for minimal common CNA regions in colorectal adenomas.
adenomas and intramucosal adenocarcinomas but could not find minimal common CNA regions in more than 30% of cases in the tumours examined.

Although none of the CNAs found in more than 30% of cases were detected in low-grade colorectal adenomas, regions of gain located at 7q11.22-23, 7q11.1-11.21, 7q21.11-36.3, 7p11.2-22.3 and 9p13.1 (in decreasing order of frequency) were detected in more than 30% of high-grade colorectal adenomas. Regions of copy-neutral LOH detected in more than 30% of cases were found at 5q15-35.3 and 5q14.3 in high-grade colorectal adenomas. LOH was not detected in either low-grade or high-grade colorectal adenomas. In intramucosal adenocarcinomas, regions of gain defined in more than 30% of cases were found at 13q11, q14.2, q22.2-33.1, 13q32.2, 13q34, 7q11.21, 20q13.33, 7p12.3-22.3, 7q11.22-36.3, 8p11.21-11.22, 20q11.21-13.32, 7p11.2-12.2, 8q21.11-24.13, 7p12.1-13.13, 18p11.31-32, 17p12, 18q12.1-12.3. Whereas regions of copy-neutral LOH detected in more than 30% of cases were found at 5q14.1 and 5q14.2-35.3 in intramucosal adenocarcinomas, no LOH events were found in intramucosal adenocarcinomas. These results are summarized in Table 2.

### Table 2: Frequent copy number alteration regions in colorectal adenomas and intramucosal adenocarcinoma (IMA)

| Chromosomal regions | LGA (n = 35) | Chromosomal regions | HGA (n = 20) | Chromosomal regions | IMA (n = 30) |
|---------------------|-------------|---------------------|-------------|---------------------|-------------|
| Gain                | Gain        | Gain                | Gain        |
| None                | 7q11.22-23  | 7 (35.0%)           | 13q12.13-12.2, q13.2-13.3 | 18 (60.0%) |
| CNLOH               | 7q11.1-11.21| 6 (30.0%)           | 13q31.1-32.1, q33.2-3 | 17 (56.7%) |
| None                | 7q21.11-36.3| 6 (30.0%)           | 13q21.1-22.1 | 6 (30.0%) |
| LOH                 | 7p11.2-22.3 | 6 (30.0%)           | 13q14.11-14.13, q14.3 | 17 (56.7%) |
| None                | 9p13.1      | 6 (30.0%)           | 13q12.11-12.12, q12.3-13.1 | 17 (56.7%) |
| CNLOH               | 5q15-35.3   | 8 (40.0%)           | 13q32.2-32.3 | 15 (50.0%) |
| LOH                 | 5q14.3      | 7 (35.0%)           | 13q34       | 14 (46.7%) |
| None                | 7q11.21, 20q13.33 | 13 (43.3%)  | 7p12.3-22.3, 7q11.22-36.3 | 12 (40.0%) |
| CNLOH               | 8p11.21-11.22 | 12 (40.0%)  | 8q11.21-13.32 | 12 (40.0%) |
| LOH                 | 5q14.1      | 10 (33.3%)          | 13q14.11-14.13, 13q14.3, 13q12.11-12.12, 13q12.3-13.1, 13q11, 13q14.2, 13q22.2-33.1, 13q32.2-32.3, 13q34, 7q11.21, 20q13.33, 7p12.3-22.3, 7q11.22-36.3, 8p11.21-11.22, 20q11.21-13.32, 7p11.2-12.2, 8q21.11-24.13, 20q12.13-13, 18p11.31-32, 17p12 and 18q12.1-12.3. Whereas regions of copy-neutral LOH detected in more than 30% of cases were found at 5q14.1 and 5q14.2-35.3 in intramucosal adenocarcinomas, no LOH events were found in intramucosal adenocarcinomas. These results are summarized in Table 2.

**Table 2** Frequent copy number alteration regions in colorectal adenomas and intramucosal adenocarcinoma (IMA)

| Chromosomal regions | LGA (n = 35) | Chromosomal regions | HGA (n = 20) | Chromosomal regions | IMA (n = 30) |
|---------------------|-------------|---------------------|-------------|---------------------|-------------|
| Gain                | Gain        | Gain                | Gain        |
| None                | 7q11.22-23  | 7 (35.0%)           | 13q12.13-12.2, q13.2-13.3 | 18 (60.0%) |
| CNLOH               | 7q11.1-11.21| 6 (30.0%)           | 13q31.1-32.1, q33.2-3 | 17 (56.7%) |
| None                | 7q21.11-36.3| 6 (30.0%)           | 13q21.1-22.1 | 6 (30.0%) |
| LOH                 | 7p11.2-22.3 | 6 (30.0%)           | 13q14.11-14.13, q14.3 | 17 (56.7%) |
| None                | 9p13.1      | 6 (30.0%)           | 13q12.11-12.12, q12.3-13.1 | 17 (56.7%) |
| CNLOH               | 5q15-35.3   | 8 (40.0%)           | 13q32.2-32.3 | 15 (50.0%) |
| LOH                 | 5q14.3      | 7 (35.0%)           | 13q34       | 14 (46.7%) |
| None                | 7q11.21, 20q13.33 | 13 (43.3%)  | 7p12.3-22.3, 7q11.22-36.3 | 12 (40.0%) |
| CNLOH               | 8p11.21-11.22 | 12 (40.0%)  | 8q11.21-13.32 | 12 (40.0%) |
| LOH                 | 5q14.1      | 10 (33.3%)          | 13q14.11-14.13, 13q14.3, 13q12.11-12.12, 13q12.3-13.1, 13q11, 13q14.2, 13q22.2-33.1, 13q32.2-32.3, 13q34, 7q11.21, 20q13.33, 7p12.3-22.3, 7q11.22-36.3, 8p11.21-11.22, 20q11.21-13.32, 7p11.2-12.2, 8q21.11-24.13, 20q12.13-13, 18p11.31-32, 17p12 and 18q12.1-12.3. Whereas regions of copy-neutral LOH detected in more than 30% of cases were found at 5q14.1 and 5q14.2-35.3 in intramucosal adenocarcinomas, no LOH events were found in intramucosal adenocarcinomas. These results are summarized in Table 2.

**Genomic differences between low-grade and high-grade colorectal adenomas and between high-grade colorectal adenomas and intramucosal adenocarcinomas**

Next, we examined differences in CNAs between low-grade and high-grade colorectal adenomas and between high-grade colorectal adenomas and intramucosal adenocarcinomas. We compared regions of gain detected in more than 30% of cases between low-grade colorectal adenomas and high-grade colorectal adenomas. Significant differences in gains between low-grade and high-grade colorectal adenomas were found at 7p22.2-22.3. However, no significant differences in the frequencies of copy-neutral LOH or LOH were found between low-grade and high-grade colorectal adenomas.

We also compared the regions of gain detected in more than 30% of cases between high-grade colorectal adenomas and intramucosal adenocarcinomas. Significant differences in gains between high-grade colorectal adenomas and intramucosal adenocarcinomas were found at 13q12.13-2, 13q13.2-3, 13q12.11-13.1, 13q14.11-14.13, 13q11, 13q14.2, 13q32.2, 13q21.2, 13q32.1, 13q33.2-3, 13q22.2-33.1, 13q14.3-21.1, 13q21.31-33, 13q31.1-3, 13q32.3, 13q34, 17p12, 17p11.2, 17p13.1-13.2 and

 Springer
18p11.31-32 (Table 3). However, differences in regions of copy-neutral LOH and LOH were not detected between high-grade colorectal adenomas and intramucosal adenocarcinomas.

### Difference in CNA length on a genome-wide scale in colorectal adenomas and intramucosal adenocarcinomas

Overall, the total length of CNAs was greater in high-grade colorectal adenoma than in low-grade colorectal adenoma (Fig. 2; \( P < 0.001 \)) and greater in intramucosal adenocarcinoma than in low-grade colorectal adenoma. Genomic losses (LOH and copy-neutral LOH) and gains were investigated separately. The total length of copy number gains was significantly greater in high-grade colorectal adenoma than in low-grade colorectal adenoma (Fig. 2; \( P < 0.001 \)) and significantly greater in intramucosal adenocarcinoma than in low-grade colorectal adenoma (Fig. 2; \( P < 0.001 \)). Although there was a significant difference in the total length of LOH between low-grade and high-grade colorectal adenoma (Fig. 2; \( P < 0.05 \)), no differences in copy-neutral LOH between low-grade colorectal adenoma and high-grade colorectal adenoma were detected. No significant differences in the total length of losses (LOH and copy-neutral LOH) were found between high-grade colorectal adenoma and intramucosal adenocarcinoma.

### Genomic differences in low-grade colorectal adenomas, high-grade colorectal adenomas and intramucosal adenocarcinomas between left-sided and right-sided tumours

We examined CNAs of low-grade adenomas, high-grade adenomas, and intramucosal adenocarcinomas for left-sided and right-sided tumours. However, there were no significant differences in the frequencies of CNAs between left-sided and right-sided tumours in low-grade adenomas, high-grade adenomas, and intramucosal adenocarcinomas. These data are shown in Table S1.

### Genomic differences in low-grade colorectal adenomas, high-grade colorectal adenomas and intramucosal adenocarcinomas between rectal and colonic tumours

Next, we examined CNAs in low-grade adenomas, high-grade adenomas, and intramucosal adenocarcinomas of the rectum and the colon. Although there were no differences in the frequencies of CNAs between the rectum and the colon for low-grade adenomas, a significant difference in the frequencies of CNAs between the rectum and the colon was observed for high-grade adenomas (gains at 8q23.2-3, 8p11.1 and p11.21-23.3). In addition, there were significant differences in the frequencies of CNAs between the rectum and the colon for intramucosal adenocarcinomas (greater for the rectum than for the colon: gains at 16q22.1-24.3, 21q21.3-22.3, 10q11.21-23, 10p11.1, 12q13.13-15, q21.2, TABLE 3 Significant differences in the frequencies of copy number alterations between high-grade colorectal adenoma (HGA) and intramucosal adenocarcinoma (IMA)

| Chromosomal regions | HGA (n = 20) | IMA (n = 30) | P     |
|---------------------|-------------|-------------|-------|
| **Gain**            |             |             |       |
| 13q12.13-2, 13q13.2-3 | 0           | 18 (60.0%)  | <0.001|
| 13q12.11-13.1, 13q14.11-14.13 | 0           | 17 (56.7%)  | <0.001|
| 13q11, 13q14.2      | 0           | 16 (53.3%)  | <0.001|
| 13q32.2             | 0           | 15 (50.0%)  | <0.001|
| 13q21.2, 13q22.1, 13q32.1, 13q33.2-3 | 1 (5.0%)    | 17 (56.7%)  | <0.01 |
| 13q22.2-33.1        | 1 (5.0%)    | 16 (53.3%)  | <0.01 |
| 13q14.3-21.1, 13q21.31-33, 13q31.1-3 | 2 (10.0%)   | 17 (56.7%)  | <0.01 |
| 13q32.3             | 1 (5.0%)    | 15 (50.0%)  | <0.01 |
| 13q34               | 1 (5.0%)    | 14 (46.7%)  | <0.01 |
| 17p12               | 0           | 9 (30.0%)   | 0.02  |
| 17p11.2, 17p13.1-13.2 | 0           | 8 (26.7%)   | 0.03  |
| 18p11.31-32         | 1 (5.0%)    | 10 (33.3%)  | 0.04  |

**CNLOH** copy-neutral loss of heterozygosity, **LOH** loss of heterozygosity
q24.32, 12p11.1-13.31, 16q11.2-13.3 and 21q11.2-21.2; LOH at 16p13.3). The detailed results are shown in Table S2.

Representative features of the pathological and molecular findings in colorectal adenoma (low grade and high grade) and intramucosal adenocarcinoma are shown in Fig. 3.

Discussion

This study focused on the comprehensive genetic characterization of colorectal tumours occurring in the progression of colorectal adenoma to colorectal intramucosal adenocarcinoma. Recent studies have shown that DNA methylation is one of the major epigenetic mechanisms closely associated with development of low-grade colorectal adenoma [6, 7]. Although epigenetic alterations play an essential role in the early progression of CRC [23], genomic changes are also closely associated with the progression of CRC [6]. Genomic changes are classified into two groups: genomic gains and losses. In addition, genomic losses can be subclassified into two subgroups (i.e., LOH and copy-neutral LOH) with use of an SNP array. LOH and copy-neutral LOH are common mechanisms of inactivating the expression of tumour-suppressor genes [9]. To the best of our knowledge, this is the first study that has systematically used high-resolution SNP arrays to extensively compare genetic abnormalities found in colorectal adenomas and intramucosal adenocarcinomas. The present results may be of great clinical and pathological utility for the identification of patients with colorectal tumours at higher risk of tumour progression.

Contamination of tumour tissues with interstitial cells makes it difficult to accurately examine molecular alterations [19, 20]. In the present study, we used the crypt isolation method to analyse only the tumour epithelial component in the tumour tissue. Our previous reports have emphasized that isolation of the tumour glands is indispensable for evaluation of molecular alterations in gland-forming tumours [3, 19, 20]. In the present study, we successfully isolated tumour glands from all tumour tissues. Therefore, we could provide a reliable molecular analysis for understanding colorectal carcinogenesis using high-density SNP arrays [3, 19, 20].

In the present study, although no CNAs (gains and losses) detected in more than 30% of low-grade colorectal adenomas were observed, we identified frequently altered
chromosomal sites in high-grade colorectal adenomas (gains at 7q11-36, 7p11 and 9p13, and copy-neutral LOH at 5q14-35). This finding suggests that accumulation of CNAs may not be necessary for the development of low-grade colorectal adenoma. On the basis of this evidence, we suggest that although genetic (chromosomal) and epigenetic alterations contribute to the pathogenesis of CRC, epigenetic alterations rather than chromosomal alterations are more important for development of low-grade colorectal adenoma [6, 7].

Multiple CNAs characterize molecular alteration of CRC according to previous reports, which have shown that accumulation of CNAs is necessary for progression of CRC [6, 7, 24]. The present study identified a number of focal genomic gains (at 13q12, 13q13, 13q31, 13q33, 13q21, 13q14, 13q12, 13q11, 13q14, 13q22, 13q32, 13q34, 7q11, 20q13, 7p12-22, 7q12-36, 8p11, 20q11-13, 7p11-12, 8q21-24, 20q12-13, 18p11, 17p12 and 18q12) and losses (copy-neutral LOH at 5q14-35) in colorectal intramucosal adenocarcinoma. These findings showed some concordance with the results from previous studies of CRC [16, 17]. However, to the best of our knowledge, this study is the first genome-wide report of genetic alterations in intramucosal adenocarcinoma. Although multiple genetic events accompanying the loss of genetic material caused by acquisition of LOH are required for tumour progression,
our results suggest that gain of multiple chromosomal loci rather than genetic losses contributes to early colorectal carcinogenesis. Therefore, we suggest that molecular alterations may be characterized by chromosomal gains, which cause genomic instability as a result of DNA aneuploidy.

In a previous study, we examined genome-wide CNAs in advanced CRCs [22]. There were numerous CNAs in advanced CRCs in our previous study [22], and regions of gain detected in more than 50% of cases were located at 18q21.2-22.3, 18q11.1-12.3, and 18q11.21-11.32. Although regions of LOH detected in more than 50% of cases were found at 18q21.2-22.3, 18q23, and 18q12.1-12.3, no regions with copy-neutral LOH in more than 50% of cases were detected [22]. Our findings are similar to those of previous reports in terms of the occurrence of multiple genomic changes in invasive CRC [24, 25]. These results indicate that there are several well-defined CNAs, including gains at 1q, 7p/q, 8p/p, 12q, 13q, 19q, and 20p/q, and losses at 18p/q and 17p/q [25]. In addition, significant genomic losses were observed at 1p, 4q, 5q, 8p, 14q, 15q, 20p, and 22q [25].

Another study investigated genomic changes in primary CRC and metastatic lesions [13], and revealed a characteristic pattern of CNAs in metastatic lesions from CRC that involved losses of regions at 1p, 17p, and 18q and gains of regions at 7 and 13q [13]. These findings suggest that acquisition of increasing genomic changes (CNAs) occurring in the tumour cell plays a major role in the progression or metastasis of CRC. From the results taken together, although we found that high levels of gains in intramucosal adenocarcinomas were detected at 13q, 7q, 8p, 20q, 7p, 18p, and 17p in the present study, gains at 13q were common genomic changes in advanced CRC.

The most striking difference in chromosomal alterations between high-grade colorectal adenoma and intramucosal adenocarcinoma was an increase in the number of specific regions of gain, as detected with a high-resolution SNP array. The significance of this result in terms of tumour pathogenesis is not yet clear. In the present study, we showed that gains at 13q, 17p, and 18p might play an essential role in early colorectal carcinogenesis. In particular, we suggest that gain at 13q is closely associated with progression to intramucosal adenocarcinoma from high-grade colorectal adenoma. We also searched for specific genes associated with colorectal carcinogenesis. If the regions at specific loci that we examined contribute to tumour progression, the product of the candidate gene is expected to be overexpressed in a given tissue. Although we could not find minimal common regions of CNAs (more than 30% of cases) in colorectal adenomas and intramucosal adenocarcinomas in the present study, we propose that three candidate genes—FGF9 (which encodes fibroblast growth factor 9), FLT1 (which encodes vascular endothelial growth factor receptor 1), also known as Fms-like tyrosine kinase 1) and KLF5 (which encodes Krüppel-like factor 5), located at 13q11-12, 13q12 and 13q22.1 respectively—may be involved in tumour progression, in agreement with previously published studies (FGF9 [26, 27], FLT1 [28, 29] and KLF5 [28–32]). Although these genes are found to be overexpressed in several malignant tumours, including gastric and colon cancers, it remains unclear whether the products of FGF9, FLT1 and KLF5 are overexpressed in colorectal intramucosal adenocarcinoma [26–28, 31]. Further examination of the expression of these genes is required.

The total length of CNAs is expected to be one of the factors closely associated with the level of genetic instability in tumour cells [33]. Although DNA aneuploidy is a classic factor representing chromosomal instability in tumour cells [34], the total length of CNAs may become a novel factor for identification of chromosomal instability of tumour cells [35]. In the present study, there were significant differences in the total lengths of overall CNAs and copy number gain between low-grade and high-grade colorectal adenomas. However, the significance of differences in the total length of copy number LOH between them was low. This finding suggests that although high-grade colorectal adenoma seems to be adenomatous histologically, such cells may acquire a higher level of chromosome instability at the high-grade lesion stage. On the other hand, no significant differences in the total lengths of CNAs (overall, LOH, copy-neutral LOH or gain) were found between high-grade adenoma and intramucosal adenocarcinoma, in contrast to the comparison of low-grade adenoma with high-grade adenoma. This finding suggests that although the histological difference between high-grade adenoma and intramucosal adenocarcinoma is clear to some extent, the molecular alterations in high-grade adenoma are similar to those in intramucosal adenocarcinoma at the level of chromosomal instability [16, 17]. In addition, this finding is highly useful to predict aggressive behaviour in terms of transformation to a more high-grade tumour from a low-grade tumour [36].

The Cancer Genome Atlas (TCGA) has identified comprehensive genetic alterations of various malignant tumours, including colorectal tumours [24]. Tumour genome data obtained from TCGA is considered standard genetic data worldwide. However, we do not think TCGA data are directly comparable with data of other studies given that the TCGA platform is different from that of other studies, including our own. In addition, genetic alterations in colorectal adenoma and intramucosal adenocarcinoma from TCGA data have not been fully clarified. We believe that our results contribute to the understanding of colorectal tumorigenesis.
According to previous studies, there are major differences in CRC when it occurs on the right side compared with the left side [22, 37, 38]. Previous studies showed that classification based on tumour location (i.e., left-sided CRC and right-sided CRC) is also useful and essential for evaluation of colorectal carcinogenesis [22, 37, 38]. In the present study, although we examined CNAs of low-grade adenoma, high-grade adenoma, and intramucosal adenocarcinoma for left-sided and right-sided tumours, no significant differences between them were found. Thus, because we did not identify distinct differences between left-sided and right-sided tumours, further examinations are required.

Previous studies suggested that the development of rectal and colonic cancers may involve different mechanisms [39, 40]. We examined CNAs of low-grade adenoma, high-grade adenoma, and intramucosal adenocarcinoma of the rectum and the colon. Although there were no differences in the frequency of CNAs between the rectum and the colon in low-grade adenoma, a significant difference in the frequency of CNAs between the rectum and the colon was observed for high-grade adenoma (gains at 8q23.2-3, 8p11.1 and p11.21-23.3). Moreover, there were significant differences in the frequencies of CNAs between the rectum and the colon for intramucosal adenocarcinomas (greater for the rectum than for the colon: gains at 16q22.1-24.3, 21q11.3-22.3, 10q11.21-23, 10p11.1, 12q13.13-15, q21.2, q24.32, 12p11.1-13.31, 16q11.2-13 and 21q11.2-21.2; LOH at 16p13.3). These data along with existing evidence for the presence of distinct genetic profiles may be supportive of the concept that rectal and colonic CRCs are distinct molecular entities [39, 40]. However, the conclusions derived from our findings are limited because of the small number of cases, and thus further studies with greater numbers of cases are needed.

Although elucidation of the molecular differences between adenoma and intramucosal adenocarcinoma within the same tumour may be needed to evaluate the early stages of colorectal carcinogenesis, it is difficult to evaluate differences between lesions within an individual tumour. In fact, distinguishing adenomatous lesions (in particular, high-grade adenoma) from intracarcinomatous lesions on the basis of surface macroscopic findings is very difficult. We will examine differences in genome-wide alterations within the same tumour in future studies.

In conclusion, we attempted to better define the molecular mechanism that initiates chromosomal instability during colorectal tumorigenesis. Identification of the relationship between chromosomal instability and tumour progression and the feasibility of targeting chromosomally unstable cells will be effective in advancing our understanding of tumour characteristics during the initial phases of colorectal tumorigenesis.

Acknowledgements We gratefully acknowledge the technical assistance of E. Sugawara and T. Kasai. We also thank the members of the Department of Molecular Diagnostic Pathology, Iwate Medical University, for their support.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22:191–7.
2. Yasuda K, Inomata M, Shiromizu A, et al. Risk factors for occult lymph node metastasis of colorectal cancer invading the submucosa and indications for endoscopic mucosal resection. Dis Colon Rectum. 2007;50:1370–6.
3. Sugai T, Habano W, Uesugi N, et al. Molecular validation of the modified Vienna classification of colorectal tumors. J Mol Diagn. 2002;4:191–200.
4. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med. 1988;319:525–32.
5. Jass JR, Whitehall VL, Young J, et al. Emerging concepts in colorectal neoplasia. Gastroenterology. 2002;123:862–76.
6. Yamamoto E, Suzuki H, Yamano HO, et al. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype. Am J Pathol. 2012;181:1847–61.
7. Yagi K, Takahashi H, Akagi K, et al. Intermediate methylation epigenotype and its correlation to KRAS mutation in conventional colorectal adenoma. Am J Pathol. 2012;180:616–25.
8. Kaneda A, Yagi K. Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes. Cancer Sci. 2011;102:18–24.
9. Melcher R, Hartmann E, Zopf W, et al. LOH and copy neutral LOH (cnLOH) act as alternative mechanism in sporadic colorectal cancers with chromosomal and microsatellite instability. Carcinogenesis. 2011;32:636–42.
10. Wang H, Liang L, Fang JY, et al. Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers. Oncogene. 2016;35:2011–9.
11. van Puijenbroek M, Middeldorp A, Tops CM, et al. Genome-wide copy neutral LOH is infrequent in familial and sporadic microsatellite unstable carcinomas. Fam Cancer. 2008;7:319–30.
12. González-Gonzálezm, Fontanillo C, Abad MM, et al. Identification of a characteristic copy number alteration profile by high-resolution single nucleotide polymorphism arrays associated with metastatic sporadic colorectal cancer. Cancer. 2014;120:1948–59.
13. Muñoz-Bellvis L, Fontanillo C, González-González M, et al. Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumors as defined by high-density single-nucleotide polymorphism arrays. Mod Pathol. 2012;25:590–601.

14. Sayagues JM, Abad Mdel M, Melchor HB, et al. Intratumoural cytogenetic heterogeneity of sporadic colorectal carcinomas suggests several pathways to liver metastasis. J Pathol. 2010;223:308–19.

15. Xiao XY, Zhou XY, Yan G, et al. Chromosomal alteration in Chinese sporadic colorectal carcinomas detected by comparative genomic hybridization. Diagn Mol Pathol. 2007;16:96–103.

16. He Qi, Zeng WF, Sham JS, et al. Recurrent genetic alterations in 26 colorectal carcinomas and 21 adenomas from Chinese patients. Cancer Genet Cytogenet. 2003;144:112–8.

17. Meijer GA, Hermens MA, Baak JP, et al. Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation. J Clin Pathol. 1998;51:901–9.

18. Hamilton SR, Bosman FT, Boffetta P, et al. Carcinoma of the colon and rectum. In: Bozman FT, Carneiro F, Hruban RH, et al., editors. WHO classification of tumours pathology and genetics tumours of the digestive system. Lyon: IARC; 2010. p. 134–46.

19. Habano W, Sugai T, Nakamura S, et al. A novel method for gene analysis of colorectal carcinomas using a cryopreservation technique. Lab Investig. 1996;74:933–40.

20. Sugai T, Habano W, Nakamura S, et al. A unique method for mutation analysis of tumor suppressor genes in colorectal carcinomas using a cryopreservation technique. Arch Pathol Lab Med. 2000;124:382–6.

21. Arakawa N, Sugai T, Habano W, et al. Genome-wide analysis of DNA copy number alterations in early and advanced gastric cancers. Mol Carcinog. 2017;56:527–37.

22. Takahashi Y, Sugai T, Hanabo W, et al. Molecular differences in the microsatellite stable phenotype between left-sided and right-sided colorectal cancer. Int J Cancer. 2016;139:2493–501.

23. Toyoda M, Aihara N, Ohe-Toyoda M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:3681–6.

24. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7.

25. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108–13.

26. Ren C, Chen H, Han C, et al. The anti-apoptotic and prognostic value of fibroblast growth factor 9 in gastric cancer. Oncotarget. 2016;7:36655–65.

27. Chen TM, Shih YH, Tseng JT, et al. Overexpression of FGF9 in colon cancer cells is mediated by hypoxia-induced translational activation. Nucleic Acids Res. 2014;42:2932–44.

28. Zhang SA, McCrudden CM, Meng C, et al. The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab. Onco Targets Ther. 2015;8:835–43.

29. Wei SC, Tsao PN, Weng MT, et al. Flt-1 in colorectal cancer cells is required for the tumor invasive effect of placental growth factor through a p38-MAPK pathway. J Biomed Sci. 2013;20:39.

30. Nakaya T, Ogawa S, Manabe I, et al. KLF5 regulates the integrity and oncoigenicity of intestinal stem cells. Cancer Res. 2014;74:2882–91.

31. Soon MS, Hsu LS, Chen CJ, et al. Expression of Krüppel-like factor 5 in gastric cancer and its clinical correlation in Taiwan. Virchows Arch. 2011;459:161–6.

32. Kwak MK, Lee HJ, Hur K, et al. Expression of Krüppel-like factor 5 in human gastric carcinomas. J Cancer Res Clin Oncol. 2008;134:163–7.

33. Sugai T, Habano W, Nakamura S, et al. Genetic alterations in DNA diploid, aneuploid and multiploid colorectal carcinomas identified by the crypt isolation technique. Int J Cancer. 2000;88:614–9.

34. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138:2059–72.

35. Sawada T, Yamamoto E, Suzuki H, et al. Association between genomic alterations and metastatic behavior of colorectal cancer identified by array-based comparative genomic hybridization. Genes Chromosomes Cancer. 2013;52:140–9.

36. Xie T, D’Ario G, Lamb JR, et al. A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations. PLoS One. 2012;7:e42001. doi:10.1371/journal.pone.0042001.

37. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer. 2002;101:403–8.

38. Sugai T, Habano W, Jiao Y-F, et al. Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas. J Mol Diagn. 2006;8:193–201.

39. Minoo P, Zlobec I, Peterson M, et al. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol. 2010;37:707–18.

40. Kapiteijn E, Liefers GJ, Los LC, et al. Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol. 2001;195:171–8.